Moloney G, Garcerant Congote D, Hirnschall N, et al. - Researchers conducted the study for reporting early safety and effectiveness of Descemet stripping only (DSO) supplemented with ripasudil. The study received ethics approval and was conducted under the supervision of the data security monitoring board. All registered candidates had a superior endothelial cell count of > 1000 cells/mm ² and were symptomatic from the presence of central guttata degrading vision and/or producing glare. Twenty-three eyes of 23 patients met the criteria for inclusion and underwent DSO. The local and systemic safety analysis included this DSO trial supplemented with ripasudil. The authors believe that this treatment option is emerging as a reliable intervention for selected patients with Fuchs' Endothelial Corneal Dystrophy with an acceptable safety profile. Powerful proof of a drug reaction is the observation of relapse edema. The longevity of such outcomes remains uncertain.